Alpha Cognition is continuing to look like a strong buy in the pre-revenue biopharma market.
$ACOG’s ALPHA-1062 belongs to a class of drugs that are currently the standard form of care for Alzheimer's. The benefit of ALPHA-1062 is that it offers effective treatment without the majority of gastrointestinal side effects brought on by other drugs in the same class. 45% of patients who discontinue the use of these acetylcholinesterase inhibitor drugs (AChEI), do so for these reasons.
With the AChEI market being around $5 billion, capturing even a small percent of this market represents a massive opportunity for $ACOG, currently valued at $63.96 million.
$ACOG.V has strong data on ALPHA-1062 with a low bar for approval where it requires only bioequivalence rather than efficacy. This makes its Phase 3 trial faster and smaller than typical, with a New Drug Application planned for 2022.
With some analysts speculating a $5 price target for $ACOG, that puts potential earnings at this point around 382%.
$ACOG is currently trading at $1.04 and is valued at an MCAP of $63.96 million.
https://www.cantechletter.com/2021/12/three-canadian-biopharma-stocks-for-2022/#